Athos Therapeutics

Immunology (private biotech)

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
G9A (EHMT2)Small molecule
Inflammatory Bowel Disease
Ulcerative Colitis

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
December 2028 (1)
ATH-063Phase 2Ulcerative Colitis, Inflammatory Bowel Diseases, Autoimmune Diseases
Est. primary completion 2028-12-14 · NCT07513181 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.